PainCeptor Pharma Corporation, a new leading-edge biopharmaceutical company, emerged today as the result of a merger of Antalium Inc. and Neuroceptor Inc., two spin-off companies of McGill and Queen’s Universities, respectively. The new Company is focused on the development of novel and effective therapeutic drugs for the treatment of acute and chronic pain. The merger was led by Louis R. Lamontagne, Ph.D., the new CEO of PainCeptor and former CEO of Neurochem Inc. Dr. Lamontagne has successfully completed an initial private placement of CAN$23 million to finance the Company. PainCeptor Pharma will operate from facilities in Montreal, Quebec and Kingston, Ontario.
